Business Context and Reporting Period
This Form 8-K filing by ReWalk Robotics Ltd. (noted as Lifeward Ltd. in metadata) covers events occurring on March 27, 2019, and effective April 1, 2019. The report details the results of the Company's 2019 Annual Meeting of Shareholders and the subsequent implementation of a reverse share split and amendments to the Articles of Association.
Key Financial Metrics and Capital Structure
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data relates to capital structure adjustments:
- Reverse Share Split: A one-for-twenty-five (1:25) reverse split of ordinary shares became effective April 1, 2019.
- Authorized Capital: The total number of authorized ordinary shares was reduced from 250,000,000 to 60,000,000.
- Par Value: The par value per share increased from NIS 0.01 to NIS 0.25.
- Total Authorized Capital: Increased from NIS 2,500,000 to NIS 15,000,000.
- Warrant Adjustments: Exercise prices for outstanding warrants were adjusted proportionately (e.g., November 2016 warrants adjusted to $118.75; November 2018 warrants adjusted to $7.50).
Material Changes Versus Prior Period
The filing reports significant corporate governance and structural changes approved by shareholders:
- Shareholder Voting: 53,304,002 shares (72.8% of outstanding voting shares) were present or voted at the March 27, 2019 meeting.
- Board Elections: Class II directors Larry Jasinski, Ning Cong, and John William Poduska were re-elected.
- Corporate Actions: Shareholders approved the reverse share split, an increase in authorized share capital, and specific equity awards and compensation policy amendments for the CEO.
- Accounting Firm: Kost Forer Gabbay & Kasierer was reappointed as the independent registered public accounting firm for 2019.
Guidance, Outlook, Risks, and Contingencies
Management commentary and risk disclosures highlight significant operational and financial challenges:
- Going Concern: The filing explicitly states there are "substantial doubts as to ReWalk's ability to continue as a going concern," a conclusion shared by management and previous auditors.
- Liquidity and Capital: Risks include the ability to secure capital from equity and debt financings, potential dilution, and restrictions on business operations due to financing limitations.
- Nasdaq Compliance: The reverse split was executed to regain compliance with Nasdaq Capital Market listing requirements. There is a risk of delisting if compliance is not maintained.
- Operational Risks: Key risks include the ability to achieve reimbursement from third-party payors, regulatory approvals (including FDA post-market surveillance), product market acceptance, and ongoing shareholder class action litigation regarding the IPO.
- Debt Obligations: The Company faces risks regarding its ability to repay secured indebtedness.
Investor Verification Checklist
- Verify the current trading price and volume of shares under the new CUSIP (M8216Q 200) post-split.
- Confirm the Company's current cash position and runway given the "substantial doubt" regarding going concern status.
- Review the status of the mandatory post-market 522 surveillance study and FDA regulatory developments.
- Monitor progress on securing new equity or debt financing to address liquidity needs.
- Check for updates on the shareholder class action litigation related to the initial public offering.
- Verify the Company's compliance status with Nasdaq listing requirements following the reverse split.